{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:25:19Z","timestamp":1768890319702,"version":"3.49.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,19]]},"DOI":"10.7759\/cureus.101850","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T17:21:19Z","timestamp":1768843279000},"source":"Crossref","is-referenced-by-count":0,"title":["Switching From Intravitreal Ranibizumab (Lucentis) to Biosimilar Ranibizumab (Ongavia) Injections: Insights From a Tertiary Care Eye Centre"],"prefix":"10.7759","author":[{"given":"Evdokia","family":"Sourla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naima","family":"Zaheer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randhir","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2157","article-title":"Ranibizumab","volume":"5","author":"Narayanan R","year":"2006","unstructured":"Narayanan R, Kuppermann BD, Jones C, Kirkpatrick P. Ranibizumab. Nat Rev Drug Discov. 2006, 5:815-6. 10.1038\/nrd2157","journal-title":"Nat Rev Drug Discov"},{"key":"ref2","article-title":"Ranibizumab","author":"Vaidyanathan U","year":"2025","unstructured":"Vaidyanathan U, Moshirfar M. Ranibizumab. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld PJ","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006, 355:1419-31. 10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2174\/157339909787314239","article-title":"Ranibizumab for diabetic retinopathy","volume":"5","author":"Rodriguez-Fontal M","year":"2009","unstructured":"Rodriguez-Fontal M, Alfaro V, Kerrison JB, Jablon EP. Ranibizumab for diabetic retinopathy. Curr Diabetes Rev. 2009, 5:47-51. 10.2174\/157339909787314239","journal-title":"Curr Diabetes Rev"},{"key":"ref5","unstructured":"World Health Organization. Biosimilars access toolkit. https.\/\/www.who.int\/tools\/biosimilars-access-toolkit."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02246-5","article-title":"Approved biosimilar ranibizumab-a global update","volume":"37","author":"Sharma A","year":"2023","unstructured":"Sharma A, Kondo M, Iwahashi C, et al.. Approved biosimilar ranibizumab-a global update. Eye (Lond). 2023, 37:200-2. 10.1038\/s41433-022-02246-5","journal-title":"Eye (Lond)"},{"key":"ref7","unstructured":"United Kingdom first to grant licence for Teva\u2019s ophthalmology biosimilar Ongavia (ranibizumab). (2022). Accessed. January 29, 2025: https:\/\/m.insidertracking.com\/united-kingdom-first-to-grant-licence-for-teva-s-ophthalmology-biosimilar-ongavia-ranib...."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani KG","year":"2013","unstructured":"Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013, 27:787-94. 10.1038\/eye.2013.107","journal-title":"Eye (Lond)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/APO.0000000000000445","article-title":"Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: consensus and recommendations from the Asia-Pacific Vitreo-retina Society","volume":"10","author":"Chaikitmongkol V","year":"2021","unstructured":"Chaikitmongkol V, Sagong M, Lai TY, et al.. Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: consensus and recommendations from the Asia-Pacific Vitreo-retina Society. Asia Pac J Ophthalmol (Phila). 2021, 10:507-18. 10.1097\/APO.0000000000000445","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2006.05.002","article-title":"Patient involvement in treatment decision-making: the case for a broader conceptual framework","volume":"63","author":"Entwistle VA","year":"2006","unstructured":"Entwistle VA, Watt IS. Patient involvement in treatment decision-making: the case for a broader conceptual framework. Patient Educ Couns. 2006, 63:268-78. 10.1016\/j.pec.2006.05.002","journal-title":"Patient Educ Couns"},{"key":"ref11","article-title":"Real-world outcomes of a ranibizumab biosimilar product (Ongavia) in neovascular age related macular degeneration (nAMD) patients switched from a reference ranibizumab product (Lucentis)","volume":"65","author":"Chalkiadaki E","year":"2024","unstructured":"Chalkiadaki E, Karim A, Yeung I, et al.. Real-world outcomes of a ranibizumab biosimilar product (Ongavia) in neovascular age related macular degeneration (nAMD) patients switched from a reference ranibizumab product (Lucentis). Investigative Ophthalmology & Visual Science. 2024, 65:1944.","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01616-9","article-title":"Ranibizumab biosimilar (Razumab) vs innovator ranibizumab (Lucentis) in neovascular age-related macular degeneration (N-AMD)- efficacy and safety (Bira study)","volume":"36","author":"Sharma A","year":"2022","unstructured":"Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A. Ranibizumab biosimilar (Razumab) vs innovator ranibizumab (Lucentis) in neovascular age-related macular degeneration (N-AMD)- efficacy and safety (Bira study). Eye (Lond). 2022, 36:1106-7. 10.1038\/s41433-021-01616-9","journal-title":"Eye (Lond)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-025-04030-7","article-title":"FYB-201 biosimilar ranibizumab (Ongavia\/Ranivisio\/Cimerli) efficacy and safety in clinical settings - Force study","volume":"39","author":"Sharma A","year":"2025","unstructured":"Sharma A, Nicholson L, Vazquez-Alfageme C, et al.. FYB-201 biosimilar ranibizumab (Ongavia\/Ranivisio\/Cimerli) efficacy and safety in clinical settings - Force study. Eye (Lond). 2025, 39:3129-34. 10.1038\/s41433-025-04030-7","journal-title":"Eye (Lond)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/24741264231202080","article-title":"Biosimilar to biosimilar anti-VEGF switching for retinal diseases","volume":"7","author":"Sharma A","year":"2023","unstructured":"Sharma A, Loewenstein A, Parachuri N, Kumar N, Kuppermann BD. Biosimilar to biosimilar anti-VEGF switching for retinal diseases. J Vitreoretin Dis. 2023, 7:474-6. 10.1177\/24741264231202080","journal-title":"J Vitreoretin Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/340520-switching-from-intravitreal-ranibizumab-lucentis-to-biosimilar-ranibizumab-ongavia-injections-insights-from-a-tertiary-care-eye-centre","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T17:21:21Z","timestamp":1768843281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/340520-switching-from-intravitreal-ranibizumab-lucentis-to-biosimilar-ranibizumab-ongavia-injections-insights-from-a-tertiary-care-eye-centre"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.101850","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,19]]}}}